Precipio, Inc. (PRPO) - Q1 2025 Filing Summary
Business Context and Reporting Period
Precipio, Inc. is a healthcare biotechnology company focused on cancer diagnostics, operating CLIA-certified laboratories in New Haven, Connecticut, and Omaha, Nebraska. The company develops diagnostic products and services to address cancer misdiagnoses. This summary covers the quarterly period ended March 31, 2025.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Sales | $4.93 million | $3.43 million |
| Gross Profit | $2.14 million | $0.92 million |
| Gross Margin | 43% | 27% |
| Operating Loss | $(0.86) million | $(2.07) million |
| Net Loss | $(0.88) million | $(2.08) million |
| Loss Per Share (Basic/Diluted) | $(0.59) | $(1.46) |
| Cash and Equivalents | $1.02 million | $1.50 million (Dec 31, 2024) |
| Working Capital | $(1.05) million | $(0.82) million (Dec 31, 2024) |
| Total Debt (Current + Long Term) | $0.22 million | $0.37 million (Dec 31, 2024) |
| Net Cash Used in Operating Activities | $(0.04) million | $(0.67) million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 44% year-over-year, driven primarily by a 54% increase in service revenue. This was due to a 47% increase in diagnostic cases processed (3,021 cases in Q1 2025 vs. 2,062 in Q1 2024).
- Margin Expansion: Gross margin improved significantly from 27% to 43%, attributed to economies of scale from higher case volume leveraging fixed laboratory costs.
- Loss Reduction: Net loss decreased by approximately 58% compared to the prior year, reflecting improved operational efficiency and revenue growth.
- Lease Obligations: Operating lease right-of-use assets increased significantly from $0.40 million to $1.57 million, reflecting new facility or equipment lease commitments.
Outlook, Risks, and Unusual Items
- Going Concern Warning: The company has disclosed substantial doubt about its ability to continue as a going concern for the next 12 months due to an accumulated deficit of $103.3 million and a working capital deficit. Continued operations depend on raising additional financing and achieving business plan targets.
- Change Healthcare (CHC) Impact: The company received approximately $1.1 million in temporary funding from CHC following a 2024 cyberattack. As of Q1 2025, the company has repaid $0.2 million and written off $0.1 million, with a remaining balance of approximately $0.8 million to be repaid through January 2026.
- Employee Retention Credit (ERC): In April 2025, the company received an initial ERC payment of approximately $0.4 million, expected to be recorded as other income in Q2 2025. The company is pursuing the remaining $1.1 million of the claim.
- Financing Availability: The company has an "at-the-market" sales agreement with AGP, with approximately $3.7 million remaining available for future stock sales.
- Legal Proceedings: The company is involved in a lawsuit with a former employee regarding unfair dismissal and has delinquent accounts payable with certain vendors who have threatened legal action.
Investor Verification Checklist
- Verify the timeline and certainty of the remaining $1.1 million Employee Retention Credit (ERC) claim.
- Confirm the repayment schedule and cash flow impact of the $0.8 million outstanding liability to Change Healthcare.
- Assess the sufficiency of the $3.7 million remaining under the AGP sales agreement to cover the working capital deficit and upcoming debt obligations.
- Review the status of delinquent vendor payments and potential legal risks associated with unpaid accounts payable.
- Monitor the sustainability of the 43% gross margin as case volumes fluctuate.